Evidence map›Paper›PMID 38415553›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2024

Community Screening for High-Risk Human Papilloma Virus Infection using Self-Sampling and 'Point-Of-Care' Test.

Shilpa Panta, Shalini Rajaram, Ayush Heda, Ajeet Singh Bhadoria, Deepjyoti Kalita, Latika Chawla, Jaya Chaturvedi

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shilpa PantaDepartment of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Rishikesh, India.
Shalini RajaramDepartment of Obstetrics and Gynaecology (Gynaecologic Oncology), All India Institute of Medical Sciences, Rishikesh, India.
Ayush HedaDepartment of Obstetrics and Gynaecology (Gynaecologic Oncology), All India Institute of Medical Sciences, Rishikesh, India.ORCID 0000-0002-4205-7430
Ajeet Singh BhadoriaDepartment of Community and Family Medicine, All India Institute of Medical Sciences, Rishikesh, India.
Deepjyoti KalitaDepartment of Microbiology, All India Institute of Medical Sciences, Guwahati, India.
Latika ChawlaDepartment of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Rishikesh, India.
Jaya ChaturvediDepartment of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Rishikesh, India.
All India Institute of Medical Sciences Rishikesh · INAll India Institute of Medical Sciences Guwahati · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveHR-HPV types 16 and 18 are responsible for pre-invasive and invasive lesions of the cervix, accounting for 70-80% of the total subtypes. The aim of this study was to investigate the prevalence of high-risk HPV subtypes 16 and 18 in self-collected vaginal samples using real-time micro-PCR and to study the acceptability of self-sampling.

methodsEligible women (30-65 years) were screened from a semi-urban area of Uttarakhand (India) using self-sampling. High-risk HPV genotypes (16/31 and 18/45) were tested using real-time micro-PCR technique with results available in one hour. The positive results were validated by standard RT-PCR for high-risk HPV 16, 18, separately and for 12 other high-risk genotypes, combined. Ease of the procedure, level of comfort, and recommendation to other women were studied and the acceptability of self-sampling was analyzed using the Likert scale.

resultOf 975 eligible women screened, 45 participants tested positive for HR-HPV (16/31,18/45) using real-time micro-PCR with a prevalence of 4.6%. Positive samples were further tested through routine RT-PCR and 60% were found to be HR-HPV 16 and 18 positive. For self-sampling, 96.72% (n=943) participants were 'very satisfied' and 94.15% (n=918) found self-sampling to be 'very comfortable' and 88.51% (n=863) stated that they will strongly recommend this test to other eligible women in the community.

conclusionWe conclude that HR-HPV testing with limited genotyping showed a prevalence of 4.6%, 60% of these were HPV 16/18 positive. Point of care testing was feasible in the community and self-sampling was acceptable.

Indexed as

Papillomavirus InfectionsUterine Cervical NeoplasmsEarly Detection of CancerFemaleHuman papillomavirus 16Human papillomavirus 18HumansMass ScreeningPapillomaviridaePoint-of-Care TestingSpecimen HandlingVaginal Smearscervical cancer screeningHPVmicro PCRWomen' s health

Identifiers

PMID38415553
PMCPMC11077117
OpenAlexW4392246141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.